Current and Future of Model-Based Drug Development in Japan

DOI 1 References

Bibliographic Information

Other Title
  • 日本における MBDD の現状の問題点と今後の課題

Description

Model-Based drug development (MBDD) is not so widely used Japan relative to U. S. A and EU. This is because 1) not so many well educated pharmacometricians with enough skills exist in Japan, 2) necessary databases for MBDD are not well organized in Japan. These two deficiencies lead to the paucity of disease progression model for Japanese patients. Pharmacometricians including pahramacokineticists, biostatisticians, and clinical pharmacologists have to collaborate with each other to solve these problems and contribute to the public health of Japan by ensuring development of new effective and safe drug compounds.

Journal

References(1)*help

See more

Keywords

Details 詳細情報について

  • CRID
    1390001204369106944
  • NII Article ID
    130002151414
  • DOI
    10.5691/jjb.32.s195
  • ISSN
    21856494
    09184430
  • Text Lang
    ja
  • Data Source
    • JaLC
    • Crossref
    • CiNii Articles
  • Abstract License Flag
    Disallowed

Report a problem

Back to top